Search
Stiripentol
go.drugbank.com/drugs/DB09118ApprovedInvestigational[A250825] However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs
Brincidofovir
go.drugbank.com/drugs/DB12151ApprovedInvestigational[L34470] As smallpox has been eradicated, the efficacy of Tembexa was assessed in animals infected with viruses closely related to variola. … Brincidofovir, developed by Chimerix under the brand name Tembexa, was approved by the FDA for the treatment of smallpox infection in June 2021.
Incadronic acid
go.drugbank.com/drugs/DB06255Experimental[A14426,A14431,A14427,A202769] Incadronic acid was first described in the literature in 1991.[A202289] … Along with being investigated to treat hypercalcemia of malignancy,[A202862] it has also been investigated in the treatment of myeloma, leukemia, and other cancers.
Resorcinol
go.drugbank.com/drugs/DB11085ApprovedInvestigationalIt is used as an antiseptic and disinfectant in topical pharmaceutical products in the treatment of skin disorders and infections such as acne, seborrheic dermatitis, eczema, psoriasis, corns, calluses … Although it is primarily indicated for use as a topical application, resorcinol also possesses a well-documented anti-thyroidal activity that is generally not relied upon for any kind of formal therapeutic
Methyl nicotinate
go.drugbank.com/drugs/DB13882ApprovedMethyl nicotinate is the methyl ester of [DB00627] that is used as an active ingredient as a rubefacient in over-the-counter topical preparations indicated for muscle and joint pain. … The action of methyl nicotinate as a rubefacient is thought to involve peripheral vasodilation.
Desogestrel
go.drugbank.com/drugs/DB00304ApprovedInvestigational[A176342] The first approved drug containing desogestrel was developed by Organon USA Inc in 1972 and FDA approved in 1992.[L5762] … [A176339] It was firstly generated from a study that showed that 11-beta and 11-alkylidene substituent in nortestosterone can enhance the biological activity.
CX-052075
go.drugbank.com/drugs/DB31655Approved[L53408,L53423] The original approval was formulated with the JN.1 strain ([mRNA-1283]), but was ultimately updated to the sublineage LP.8.1.[L54586] … [L53408] As opposed to previously approved COVID-19 mRNA vaccines, including the original Moderna COVID-19 vaccine ([elasomeran]), CX-052075 encodes only the immunodominant regions (NTD and RBD) of
Isavuconazole
go.drugbank.com/drugs/DB11633ApprovedInvestigationalAs isavuconazole displays low water solubility, it is found as an active ingredient of its prodrug, [DB06636]. … Resistance to isavuconazole has been associated with the mutation in the target gene CYP51 [FDA Label].
Nalmefene
go.drugbank.com/drugs/DB06230ApprovedInvestigationalWithdrawn[L1024] Nalmefene was approved in the United States in 1995 as an antidote for opioid overdose.[A245839] Nalmefene injection is used to manage known or suspected opioid overdose. … [L40684] The nasal spray formulation of nalmefene was approved by the FDA in May 2023.[L46511]
Doxercalciferol
go.drugbank.com/drugs/DB06410ApprovedInvestigationalDoxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients